Page 2 - Developmental Therapeutics Program News Today

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from...

Daniel Spratt, MD, discusses the integration of metastasis-directed therapy and hypofractionation in prostate cancer.

Amit Mahipal, MD, discusses data on camrelizumab plus rivoceranib in advanced hepatocellular carcinoma as well as the phase 3 CARES-310 trial, which is currently enrolling patients to receive the combination.

The family of a local boy who died from Osteosarcoma donated $6.4 million to the Children's Hospital of Philadelphia to advance research into rare cancer.

Daniel Spratt, MD, discusses research findings that have delineated the optimal sequencing of radiation therapy and hormone therapy for patients with prostate cancer.

Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.

In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.

In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.

/PRNewswire/ -- In a significant step for the treatment of neuroblastoma, an international group of researchers led by Childrens Hospital of Philadelphia...